POLISCOPE
Back to feed
S4323FEDERALin_committee
High Impact

Ensuring Access to Lower-Cost Medicines for Seniors Act

April 16, 2026

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced
Committee
Floor Vote
Passed
Signed

Currently in_committee. The next step in the legislative lifecycle is Floor Vote.

Last action
Read twice and referred to the Committee on Finance.Apr 16, 2026

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

Starting January 1, 2028, Medicare Part D plans must prioritize lower-cost generic and medications in their coverage and pricing structures, potentially reducing out-of-pocket costs for seniors.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Medicare Part D enrollees

Seniors and others on Medicare will have access to lower-cost generic and biosimilar drugs with reduced cost-sharing requirements.

PDP sponsors and Medicare Advantage organizations

These organizations must restructure their drug formularies and cost-sharing tiers to comply with the new inclusion and pricing mandates.

What changed

Current stage: in_committee.

What's next

Floor Vote.

Summary

This bill requires Medicare prescription drug plans to include lower-cost generic and drugs on their approved drug lists (formularies) starting in 2028. It also mandates that these plans create specific cost-sharing tiers with lower copayments for these cheaper alternatives compared to brand-name drugs.

Key Facts

  • Effective January 1, 2028, Medicare Part D plans must include generic drugs and biosimilar products on their formularies if they are cheaper than the reference brand-name drug.
  • Plans are prohibited from applying more restrictive access rules (like prior authorization or step therapy) to these lower-cost generics than they apply to the brand-name versions.
  • Plans must create at least one cost-sharing tier exclusively for generic and biosimilar drugs.
  • Copayments for the generic-only tier must be at least $20 lower than the lowest brand-name drug tier, or provide a similar actuarial reduction if using coinsurance.
  • Plans with a 'specialty tier' must create a second specialty tier exclusively for high-cost generic and biosimilar drugs.
  • The Secretary of Health and Human Services will establish uniform requirements for determining which drugs qualify and how formulary changes are implemented.
  • Determinations for formulary inclusion must be reviewed and updated on a quarterly basis during the plan year.

Frequently Asked Questions

When would these changes take effect?
The requirements apply to plan years beginning on or after January 1, 2028.
Will my Medicare plan be allowed to make it harder to get a generic drug than a brand-name drug?
No. The bill prohibits plans from imposing stricter access limits, such as or , on required generic or drugs compared to their brand-name counterparts.
How much will I save on copayments?
The bill requires that the copayment for the generic-only tier be at least $20 lower than the copayment for the lowest brand-name drug tier.

Why It Matters

Starting January 1, 2028, Medicare Part D plans must prioritize lower-cost generic and medications in their coverage and pricing structures, potentially reducing out-of-pocket costs for seniors.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Sponsors

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Mandatory Tiering

The bill shifts from allowing plans to design their own cost-sharing tiers to mandating specific 'generic-only' tiers with defined price gaps.

Connected Entities

personJames LankfordU.S. Senator who introduced the bill.Map →
personMaggie HassanU.S. Senator who co-sponsored the bill.Map →
organizationCommittee on FinanceThe Senate committee currently reviewing the bill.Map →

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record